Go Pro
→ AI billionaires are selling. Quickly. (From The Oxford Club) (Ad)tc pixel Free AKBA Stock Alerts

Akebia Therapeutics (AKBA) Financials

Akebia Therapeutics logo
$1.22 0.00 (0.00%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.23 +0.01 (+0.82%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Akebia Therapeutics

Annual Income Statements for Akebia Therapeutics

This table shows Akebia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -61 -136 -74 -144 -280 -385 -282 -94 -52 -69 -5.35
Consolidated Net Income / (Loss)		 -61 -136 -74 -144 -280 -385 -282 -94 -52 -69 -5.35
Net Income / (Loss) Continuing Operations		 -61 -136 -74 -144 -280 -385 -282 -94 -52 -69 -5.35
Total Pre-Tax Income 		-61 -136 -74 -172 -286 -385 -282 -94 -52 -69 -3.72
Total Operating Income		 -62 -136 -77 -178 -286 -378 -265 -81 -46 -50 23
Total Gross Profit		 0.00 1.54 181 200 190 -1.83 61 207 120 97 197
Total Revenue		 0.00 1.54 181 208 335 295 212 292 195 160 236
Operating Revenue		 0.00 1.54 181 208 335 295 212 292 195 160 236
Total Cost of Revenue		 0.00 0.00 0.00 7.77 145 296 151 86 74 63 39
Operating Cost of Revenue		 - 0.00 - 7.77 145 296 151 86 74 63 39
Total Operating Expenses		 62 138 258 378 476 376 325 288 167 147 173
Selling, General & Admin Expense		 18 22 27 87 149 154 174 139 100 107 107
Research & Development Expense		 43 116 231 291 323 218 148 130 63 38 62
Other Operating Expenses / (Income)		 - 0.00 - 0.07 3.53 3.41 3.49 3.18 3.24 3.22 3.40
Restructuring Charge		 - - - - - 0.00 0.00 16 0.18 0.06 0.00
Total Other Income / (Expense), net		 0.51 0.71 3.00 6.24 -0.00 -7.02 -18 -13 -5.67 -19 -27
Interest Expense		 - - - - - 0.00 0.00 0.91 0.00 0.52 0.00
Interest & Investment Income		 0.51 0.90 2.80 6.15 0.79 -8.87 -20 -16 -6.03 -18 -24
Other Income / (Expense), net		 - -0.19 0.20 0.08 -0.79 1.86 2.41 3.15 0.36 -0.24 -3.04
Income Tax Expense		 - 0.00 - -28 -6.63 0.00 0.00 - 0.00 0.00 1.62
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - - 0.00 - 0.00 0.00
Basic Earnings per Share		 ($2.29) ($3.60) ($1.69) ($2.47) ($2.36) ($2.78) ($1.70) ($0.52) ($0.28) ($0.33) ($0.02)
Weighted Average Basic Shares Outstanding		 26.47M 37.72M 43.50M 58.04M 118.40M 138.46M 165.95M 182.78M 187.47M 210.95M 257.16M
Diluted Earnings per Share		 ($2.29) ($3.60) ($1.69) ($2.47) ($2.36) ($2.78) ($1.70) ($0.52) ($0.28) ($0.33) ($0.02)
Weighted Average Diluted Shares Outstanding		 26.47M 37.72M 43.50M 58.04M 118.40M 138.46M 165.95M 182.78M 187.47M 210.95M 257.16M
Weighted Average Basic & Diluted Shares Outstanding		 26.47M 37.72M 43.50M 58.04M 118.40M 138.46M 181.23M 184.25M 209.37M 236.23M 267.88M

Quarterly Income Statements for Akebia Therapeutics

This table shows Akebia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 0.61 -18 -8.58 -20 -23 6.11 0.25 0.54 -12 -9.05
Consolidated Net Income / (Loss)		 -14 0.61 -18 -8.58 -20 -23 6.11 0.25 0.54 -12 -9.05
Net Income / (Loss) Continuing Operations		 -14 0.61 -18 -8.58 -20 -23 6.11 0.25 0.54 -12 -9.05
Total Pre-Tax Income 		-14 0.61 -18 -8.58 -20 -23 6.11 0.25 1.16 -11 -8.93
Total Operating Income		 -13 1.37 -15 -8.73 -13 -14 14 14 4.45 -8.55 -4.70
Total Gross Profit		 24 38 21 27 23 26 50 53 49 45 41
Total Revenue		 42 56 33 44 37 46 57 62 59 58 54
Operating Revenue		 42 56 33 44 37 46 57 62 59 58 54
Total Cost of Revenue		 18 19 12 17 14 20 7.63 9.92 9.38 13 12
Operating Cost of Revenue		 18 19 12 17 14 20 7.63 9.92 9.38 13 12
Total Operating Expenses		 37 36 36 35 36 40 36 38 45 54 46
Selling, General & Admin Expense		 23 25 25 27 27 28 26 27 29 26 30
Research & Development Expense		 13 9.87 9.73 7.65 8.49 12 9.75 11 15 27 15
Other Operating Expenses / (Income)		 0.86 0.86 0.71 0.76 0.77 0.98 0.70 0.90 0.90 0.90 0.71
Total Other Income / (Expense), net		 -1.45 -0.76 -3.05 0.14 -7.53 -8.50 -7.40 -14 -3.29 -2.68 -4.23
Interest & Investment Income		 -1.41 -1.42 -2.50 -2.15 -6.66 -6.88 -7.77 -6.83 -4.75 -4.83 -4.69
Other Income / (Expense), net		 -0.04 0.66 -0.03 2.29 -0.87 -1.62 0.37 -7.01 1.45 2.15 0.46
Income Tax Expense		 - - - - 0.00 - 0.00 - 0.62 - 0.13
Basic Earnings per Share		 ($0.08) $0.01 ($0.09) ($0.04) ($0.10) ($0.10) $0.03 $0.00 $0.00 ($0.05) ($0.03)
Weighted Average Basic Shares Outstanding		 188.31M 187.47M 204.96M 209.71M 210.35M 210.95M 235.50M 262.57M 264.79M 257.16M 267.05M
Diluted Earnings per Share		 ($0.08) $0.01 ($0.09) ($0.04) ($0.10) ($0.10) $0.03 $0.00 $0.00 ($0.05) ($0.03)
Weighted Average Diluted Shares Outstanding		 188.31M 187.47M 204.96M 209.71M 210.35M 210.95M 241.60M 271.10M 274.37M 257.16M 267.05M
Weighted Average Basic & Diluted Shares Outstanding		 188.39M 209.37M 209.60M 210.29M 218.18M 236.23M 262.64M 265.15M 265.37M 267.88M 268.26M

Annual Cash Flow Statements for Akebia Therapeutics

This table details how cash moves in and out of Akebia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 17 138 -117 36 43 81 -79 -59 -49 8.97 133
Net Cash From Operating Activities		 -52 58 -56 -97 -257 -110 -253 -73 -23 -41 68
Net Cash From Continuing Operating Activities		 -52 58 -56 -97 -257 -110 -253 -73 -23 -41 68
Net Income / (Loss) Continuing Operations		 -61 -136 -74 -144 -280 -385 -282 -94 -52 -69 -5.35
Consolidated Net Income / (Loss)		 -61 -136 -74 -144 -280 -385 -282 -94 -52 -69 -5.35
Depreciation Expense		 0.10 0.30 0.62 0.90 2.25 2.08 1.93 1.65 1.59 1.46 1.27
Amortization Expense		 0.56 0.49 0.61 0.29 36 33 36 36 36 36 0.00
Non-Cash Adjustments To Reconcile Net Income		 4.71 6.13 12 8.89 86 254 83 52 7.44 31 50
Changes in Operating Assets and Liabilities, net		 2.94 187 4.01 36 -102 -14 -92 -68 -17 -40 22
Net Cash From Investing Activities		 -14 13 -177 37 211 -40 40 -0.11 0.00 -0.03 -7.93
Net Cash From Continuing Investing Activities		 -14 13 -177 37 211 -40 40 -0.11 0.00 -0.03 -7.93
Purchase of Property, Plant & Equipment		 -0.41 -2.66 -1.62 -1.61 -6.66 -0.32 -0.06 -0.11 0.00 -0.03 -0.29
Acquisitions		 - 0.00 - - - - - - 0.00 0.00 -7.81
Sale of Property, Plant & Equipment		 - - - - - - - - 0.00 0.00 0.17
Net Cash From Financing Activities		 83 67 116 97 89 232 134 15 -25 50 73
Net Cash From Continuing Financing Activities		 83 67 116 97 89 232 134 15 -25 50 73
Repayment of Debt		 - - - 0.00 -15 0.00 0.00 -33 -32 -38 -0.53
Issuance of Debt		 0.01 0.02 0.01 0.02 78 20 0.00 - 0.00 45 10
Issuance of Common Equity		 83 67 115 96 26 211 89 7.53 6.79 43 67
Other Financing Activities, net		 0.13 0.12 1.31 0.65 0.13 1.23 45 40 0.00 0.39 -3.23
Cash Interest Paid		 - - - - 0.78 7.84 9.63 6.76 6.06 5.04 6.08

Quarterly Cash Flow Statements for Akebia Therapeutics

This table details how cash moves in and out of Akebia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -7.12 -3.60 -0.96 -2.46 -5.47 18 62 24 29 18 -22
Net Cash From Operating Activities		 -7.17 -2.31 -19 -10 -6.70 -4.47 -14 22 28 31 -21
Net Cash From Continuing Operating Activities		 -7.17 -2.31 -19 -10 -6.70 -4.47 -14 22 28 31 -21
Net Income / (Loss) Continuing Operations		 -14 0.61 -18 -8.58 -20 -23 6.11 0.25 0.54 -12 -9.05
Consolidated Net Income / (Loss)		 -14 0.61 -18 -8.58 -20 -23 6.11 0.25 0.54 -12 -9.05
Depreciation Expense		 0.40 0.39 0.36 0.40 0.36 0.34 0.31 0.32 0.32 0.32 0.33
Non-Cash Adjustments To Reconcile Net Income		 1.09 0.42 3.59 3.48 12 5.96 9.71 17 4.01 20 11
Changes in Operating Assets and Liabilities, net		 -3.17 -17 -14 -14 -7.66 -1.16 -30 5.10 23 23 -23
Net Cash From Investing Activities		 - - 0.00 -0.03 -0.00 -0.00 0.15 -0.13 -0.08 -7.88 -0.06
Net Cash From Continuing Investing Activities		 - - 0.00 -0.03 -0.00 -0.00 0.15 -0.13 -0.08 -7.88 -0.06
Purchase of Property, Plant & Equipment		 - - 0.00 - -0.00 -0.00 -0.02 -0.13 -0.08 -0.07 -0.06
Sale of Property, Plant & Equipment		 - - 0.00 - - - 0.17 - - - 0.00
Net Cash From Financing Activities		 0.05 -1.29 18 7.64 1.22 22 75 1.72 1.11 -4.85 -0.93
Net Cash From Continuing Financing Activities		 0.05 -1.29 18 7.64 1.22 22 75 1.72 1.11 -4.85 -0.93
Repayment of Debt		 - -8.00 -37 -0.37 -0.52 0.00 -0.53 - - - 0.00
Issuance of Debt		 - - 37 8.00 - - 10 - - - 0.00
Issuance of Common Equity		 0.05 6.71 19 - 1.75 22 65 1.54 0.15 - 0.13
Other Financing Activities, net		 - 0.00 0.14 0.01 - 0.23 0.48 0.18 0.96 -4.85 -1.06

Annual Balance Sheets for Akebia Therapeutics

This table presents Akebia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 143 300 364 997 771 644 529 356 242 221 377
Total Current Assets		 141 296 358 468 310 371 271 185 118 114 253
Cash & Equivalents		 50 187 70 105 147 229 150 90 43 52 185
Accounts Receivable		 0.00 34 34 17 39 27 52 40 39 34 47
Inventories, net		 - - 0.00 114 116 61 37 22 16 16 16
Prepaid Expenses		 2.56 2.16 6.35 16 6.63 15 33 33 20 11 5.47
Plant, Property, & Equipment, net		 0.54 2.61 3.62 8.02 10 8.62 6.75 5.21 3.63 2.20 1.22
Total Noncurrent Assets		 1.38 1.28 2.27 520 451 264 251 166 120 105 122
Goodwill		 - - 0.00 55 55 55 59 59 59 59 59
Other Noncurrent Operating Assets		 1.38 1.28 2.27 137 105 65 84 35 25 46 63
Total Liabilities & Shareholders' Equity		 143 300 364 997 771 644 529 356 242 221 377
Total Liabilities		 12 232 242 361 376 397 455 351 272 270 344
Total Current Liabilities		 12 114 141 266 208 187 261 130 100 81 163
Short-Term Debt		 - - 0.00 15 - 0.00 98 32 18 - 0.00
Accounts Payable		 2.31 2.04 7.00 43 39 41 34 18 15 15 21
Accrued Expenses		 9.56 30 52 151 129 131 109 76 68 63 122
Current Deferred Revenue		 0.00 82 82 57 40 15 21 3.74 - 0.00 2.68
Other Current Liabilities		 - - - - - - - - 0.00 2.27 17
Total Noncurrent Liabilities		 0.07 118 101 95 168 209 194 221 172 189 181
Long-Term Debt		 - - - - 76 96 0.00 34 17 39 48
Other Noncurrent Operating Liabilities		 0.01 0.03 0.02 30 59 88 173 144 112 150 133
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 131 68 123 636 395 248 74 5.23 -31 -49 33
Total Preferred & Common Equity		 131 68 123 636 395 248 74 5.23 -31 -49 33
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 131 68 123 636 395 248 74 5.23 -31 -49 33
Common Stock		 293 365 494 1,151 1,189 1,425 1,537 1,562 1,578 1,629 1,716
Retained Earnings		 -161 -297 -371 -514 -794 -1,178 -1,463 -1,557 -1,609 -1,678 -1,684
Accumulated Other Comprehensive Income / (Loss)		 -0.23 -0.04 -0.44 -0.26 0.00 0.01 0.01 0.01 0.01 0.01 0.01

Quarterly Balance Sheets for Akebia Therapeutics

This table presents Akebia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 436 281 254 235 225 220 207 310 346 364 363
Total Current Assets		 238 121 118 110 113 112 100 204 235 258 243
Cash & Equivalents		 145 0.00 54 47 42 39 34 113 137 166 163
Accounts Receivable		 23 19 20 23 27 30 32 62 73 66 63
Inventories, net		 40 20 21 18 26 24 20 20 17 19 13
Prepaid Expenses		 30 25 24 22 19 19 13 9.14 7.83 7.03 5.31
Plant, Property, & Equipment, net		 5.62 0.00 4.42 4.02 3.27 2.90 2.53 1.90 1.71 1.47 0.96
Total Noncurrent Assets		 193 59 131 121 109 105 104 104 109 104 118
Goodwill		 55 59 59 59 59 59 59 59 59 59 59
Other Noncurrent Operating Assets		 57 0.00 18 17 23 28 36 45 50 45 59
Total Liabilities & Shareholders' Equity		 436 281 254 235 225 220 207 310 346 364 363
Total Liabilities		 422 300 281 274 253 254 258 286 316 323 335
Total Current Liabilities		 188 88 92 80 66 107 66 91 119 133 174
Short-Term Debt		 66 0.00 24 8.00 0.00 0.00 0.00 - - - 12
Accounts Payable		 20 0.00 12 9.04 12 10 13 13 12 10 8.39
Accrued Expenses		 87 51 56 63 54 54 52 71 92 106 125
Current Deferred Revenue		 1.27 0.00 0.00 0.00 0.70 43 - 1.24 5.53 3.88 4.50
Other Current Liabilities		 14 0.00 - - - - - 5.99 10 13 23
Total Noncurrent Liabilities		 234 17 188 195 186 147 192 194 198 189 161
Long-Term Debt		 - 0.00 18 35 30 38 38 47 47 48 36
Other Noncurrent Operating Liabilities		 191 17 127 117 113 109 153 148 151 142 125
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 -1,584 -27 -39 -27 -34 -50 25 29 42 27
Total Preferred & Common Equity		 14 -19 -27 -39 -27 -34 -50 25 29 42 27
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 14 -1,584 -27 -39 -27 -34 -50 25 29 42 27
Common Stock		 1,559 0.00 1,568 1,570 1,600 1,602 1,605 1,697 1,701 1,713 1,720
Retained Earnings		 -1,545 -1,584 -1,595 -1,610 -1,627 -1,636 -1,656 -1,672 -1,672 -1,671 -1,693
Accumulated Other Comprehensive Income / (Loss)		 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Annual Metrics And Ratios for Akebia Therapeutics

This table displays calculated financial ratios and metrics derived from Akebia Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 11,706.32% 14.63% 61.26% -12.05% -28.17% 38.19% -33.46% -17.70% 47.46%
EBITDA Growth		 -61.76% -123.23% 44.62% -135.09% -40.91% -36.94% 34.33% 82.05% 89.94% -122.54% 264.55%
EBIT Growth		 -62.13% -122.14% 44.04% -132.88% -61.21% -30.96% 30.29% 70.38% 40.88% -10.49% 140.34%
NOPAT Growth		 -62.13% -121.84% 43.81% -132.36% -60.69% -31.97% 29.99% 69.46% 42.74% -9.11% 146.56%
Net Income Growth		 -63.95% -123.58% 45.73% -94.90% -94.76% -37.61% 26.72% 66.59% 44.89% -33.67% 92.30%
EPS Growth		 71.52% -57.21% 53.06% -46.15% 4.45% -17.80% 38.85% 69.41% 46.15% -17.86% 93.94%
Operating Cash Flow Growth		 -90.69% 210.49% -196.98% -73.60% -164.06% 57.12% -129.16% 71.08% 68.03% -73.88% 267.23%
Free Cash Flow Firm Growth		 -71.96% 320.67% -156.78% -1,181.10% 70.12% 91.28% -677.93% 88.12% 18.71% 7.21% 592.36%
Invested Capital Growth		 -54.05% -2,478.10% -1.56% 268.68% -1.95% -76.68% -71.12% -188.08% -102.66% -60.62% -66.74%
Revenue Q/Q Growth		 0.00% 0.00% 96.55% -12.88% 2.98% -4.39% 0.78% 25.66% -23.93% -5.71% 4.94%
EBITDA Q/Q Growth		 -18.39% -15.38% 41.28% -141.69% 1.23% 2.60% 9.86% 61.14% 73.29% -232.36% -14.56%
EBIT Q/Q Growth		 -18.14% -15.35% 40.87% -142.64% -1.89% 2.58% 8.34% 45.04% 12.58% -54.83% 87.02%
NOPAT Q/Q Growth		 -18.14% -15.19% 40.71% -142.75% -1.68% 2.10% 7.50% 42.81% 11.89% -45.06% 32.42%
Net Income Q/Q Growth		 -18.52% -15.29% 42.02% -111.13% -14.04% 1.56% 6.16% 41.90% 4.63% -50.91% 66.39%
EPS Q/Q Growth		 -106.62% -9.42% 46.52% -133.02% 5.60% 6.08% 10.99% 41.57% 12.50% -50.00% 71.43%
Operating Cash Flow Q/Q Growth		 -35.43% 195.43% -200.48% -142.69% -7.71% 35.72% -14.50% 10.00% 69.13% -5.61% 109.87%
Free Cash Flow Firm Q/Q Growth		 -38.89% 359.67% -164.40% -1,832.08% 74.70% 76.99% -28.98% -132.06% 78.22% 45.46% 33.29%
Invested Capital Q/Q Growth		 38.15% -217.14% 15.06% 232.99% 0.29% -39.91% -19.96% 70.51% 10.41% -35.38% -34.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 96.26% 56.62% -0.62% 28.81% 70.74% 61.90% 60.56% 83.29%
EBITDA Margin		 0.00% -8,850.68% -41.52% -85.15% -74.40% -115.84% -105.90% -13.76% -2.08% -5.62% 9.20%
Operating Margin		 0.00% -8,889.90% -42.31% -85.76% -85.46% -128.23% -124.97% -27.62% -23.77% -31.51% 9.95%
EBIT Margin		 0.00% -8,902.15% -42.20% -85.72% -85.70% -127.60% -123.83% -26.54% -23.58% -31.66% 8.66%
Profit (Net Income) Margin		 0.00% -8,843.45% -40.65% -69.12% -83.48% -130.61% -133.25% -32.22% -26.68% -43.33% -2.26%
Tax Burden Percent		 99.53% 100.00% 100.00% 83.52% 97.68% 100.00% 100.00% 100.00% 100.00% 100.00% 143.64%
Interest Burden Percent		 99.17% 99.34% 96.34% 96.54% 99.72% 102.36% 107.61% 121.37% 113.14% 136.88% -18.19%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -186.04% -61.46% -132.85% -381.53% -4,361.38% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -180.00% -19.58% -34.27% -295.26% -4,263.06% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 148.18% 7.19% 13.03% 206.16% 4,123.55% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -51.66% -136.35% -77.27% -37.86% -54.27% -119.82% -175.37% -237.83% 409.60% 174.03% 64.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -197.16% -59.49% -8.50% -271.17% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -61.67% -23.02% -26.17% -32.48% -53.13% -44.67% -17.54% -15.36% -21.93% 6.85%
Return on Assets (ROA)		 0.00% -61.26% -22.17% -21.10% -31.64% -54.38% -48.07% -21.28% -17.37% -30.02% -1.79%
Return on Common Equity (ROCE)		 -51.66% -136.35% -77.27% -37.86% -54.27% -119.82% -175.37% -237.83% 409.60% 174.03% 64.49%
Return on Equity Simple (ROE_SIMPLE)		 -46.35% -199.28% -60.10% -22.58% -70.84% -155.42% -381.07% -1,801.64% 169.78% 141.12% 0.00%
Net Operating Profit after Tax (NOPAT)		 -43 -96 -54 -125 -200 -264 -185 -57 -32 -35 16
NOPAT Margin		 0.00% -6,222.93% -29.62% -60.03% -59.82% -89.76% -87.48% -19.33% -16.64% -22.06% 6.96%
Net Nonoperating Expense Percent (NNEP)		 -14.28% -20.17% -6.92% -6.05% -41.88% -98.58% -86.27% -98.33% -119.80% -318.22% -29.10%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -789.93% 336.74% 20.34%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 3.74% 43.38% 100.62% 71.19% 29.26% 38.10% 39.44% 16.71%
SG&A Expenses to Revenue		 0.00% 1,446.91% 14.90% 41.91% 44.61% 52.30% 82.28% 47.39% 51.50% 66.52% 45.50%
R&D to Revenue		 0.00% 7,543.00% 127.41% 140.08% 96.41% 74.15% 69.86% 44.44% 32.41% 23.51% 26.40%
Operating Expenses to Revenue		 0.00% 8,989.90% 142.31% 182.02% 142.08% 127.61% 153.78% 98.36% 85.67% 92.07% 73.34%
Earnings before Interest and Taxes (EBIT)		 -62 -137 -76 -178 -287 -376 -262 -78 -46 -51 20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -136 -75 -177 -249 -341 -224 -40 -4.05 -9.01 22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.02 5.86 5.73 0.50 1.90 1.63 5.34 20.30 0.00 0.00 13.10
Price to Tangible Book Value (P/TBV)		 3.02 5.86 5.73 1.25 15.50 8.36 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 259.91 3.88 1.52 2.24 1.37 1.87 0.36 1.20 2.59 1.81
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.03 2.11 3.09 15.78 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 90.30 2.13 0.04 2.03 0.79 1.62 0.28 1.16 2.51 1.23
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.38
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14.21
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 17.67
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 2.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.27
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 1.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.01
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.02 0.19 0.39 1.32 12.63 -1.13 -0.79 1.48
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.19 0.39 0.00 6.52 -0.56 -0.79 1.48
Financial Leverage		 -1.05 -2.00 -3.03 -0.82 -0.37 -0.38 -0.70 -0.97 1.29 0.27 9.04
Leverage Ratio		 1.08 2.23 3.48 1.79 1.72 2.20 3.65 11.17 -23.58 -5.80 -36.03
Compound Leverage Factor		 1.07 2.21 3.36 1.73 1.71 2.26 3.93 13.56 -26.68 -7.93 6.55
Debt to Total Capital		 0.00% 0.00% 0.00% 2.30% 16.11% 28.02% 56.86% 92.67% 846.13% -368.79% 59.67%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 2.30% 0.00% 0.00% 56.86% 44.88% 426.93% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 16.11% 28.02% 0.00% 47.79% 419.20% -368.79% 59.67%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 97.70% 83.89% 71.98% 43.14% 7.33% -746.13% 468.79% 40.33%
Debt to EBITDA		 0.00 0.00 0.00 -0.08 -0.30 -0.28 -0.44 -1.64 -8.57 -4.30 2.22
Net Debt to EBITDA		 0.00 0.00 0.00 1.73 0.29 0.50 0.23 0.61 2.04 1.46 -6.29
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.30 -0.28 0.00 -0.85 -4.25 -4.30 2.22
Debt to NOPAT		 0.00 0.00 0.00 -0.12 -0.38 -0.36 -0.53 -1.17 -1.07 -1.10 2.93
Net Debt to NOPAT		 0.00 0.00 0.00 2.46 0.36 0.65 0.28 0.43 0.25 0.37 -8.30
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.38 -0.36 0.00 -0.60 -0.53 -1.10 2.93
Altman Z-Score		 17.97 -1.12 0.84 -0.34 -0.88 -3.07 -4.56 -5.65 -8.54 -9.58 -4.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.88 2.59 2.54 1.76 1.49 1.98 1.04 1.43 1.18 1.41 1.55
Quick Ratio		 11.67 2.57 2.49 1.27 0.90 1.58 0.77 1.01 0.82 1.07 1.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -40 89 -51 -649 -194 -17 -132 -16 -13 -12 58
Operating Cash Flow to CapEx		 -12,658.70% 2,175.28% -3,462.33% -6,070.61% -3,868.38% -34,822.71% -428,754.24% -64,170.18% 0.00% -123,209.09% 57,136.13%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -17.26 0.00 -22.81 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -80.74 0.00 -78.64 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -80.87 0.00 -78.71 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.55 0.31 0.38 0.42 0.36 0.66 0.65 0.69 0.79
Accounts Receivable Turnover		 0.00 0.00 5.33 8.17 12.07 8.97 5.40 6.37 4.89 4.35 5.80
Inventory Turnover		 0.00 0.00 0.00 0.00 1.26 3.34 3.09 2.94 3.98 3.96 2.48
Fixed Asset Turnover		 0.00 0.97 58.19 35.69 36.41 31.01 27.53 48.88 44.02 54.96 138.05
Accounts Payable Turnover		 0.00 0.00 0.00 0.31 3.54 7.36 4.02 3.32 4.54 4.24 2.17
Days Sales Outstanding (DSO)		 0.00 0.00 68.52 44.70 30.25 40.70 67.63 57.32 74.62 83.92 62.89
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 289.56 109.18 118.27 124.12 91.70 92.25 147.31
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 1,169.85 102.98 49.57 90.72 110.07 80.37 86.13 168.18
Cash Conversion Cycle (CCC)		 0.00 0.00 68.52 -1,125.15 216.83 100.32 95.19 71.37 85.95 90.04 42.03
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.46 -192 -195 329 323 75 22 -19 -39 -62 -104
Invested Capital Turnover		 0.00 -0.02 -0.94 3.10 1.03 1.48 4.36 225.60 -6.71 -3.17 -2.84
Increase / (Decrease) in Invested Capital		 -2.62 -185 -3.00 525 -6.42 -248 -54 -41 -20 -24 -42
Enterprise Value (EV)		 257 139 385 8.90 680 232 343 82 225 401 291
Market Capitalization		 396 399 703 316 752 405 395 106 234 415 427
Book Value per Share		 $4.28 $1.78 $2.59 $11.15 $3.32 $1.71 $0.42 $0.03 ($0.16) ($0.23) $0.12
Tangible Book Value per Share		 $4.28 $1.78 $2.59 $4.43 $0.41 $0.33 ($0.53) ($0.68) ($0.67) ($0.50) ($0.10)
Total Capital		 131 68 123 651 471 344 172 71 4.10 -10 81
Total Debt		 0.00 0.00 0.00 15 76 96 98 66 35 39 48
Total Long-Term Debt		 0.00 0.00 0.00 0.00 76 96 0.00 34 17 39 48
Net Debt		 -138 -260 -318 -307 -72 -172 -52 -24 -8.24 -13 -137
Capital Expenditures (CapEx)		 0.41 2.66 1.62 1.61 6.66 0.32 0.06 0.11 0.00 0.03 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.31 -78 -101 -104 -46 -84 -42 -2.82 -7.15 -19 -95
Debt-free Net Working Capital (DFNWC)		 129 182 217 218 101 184 108 88 36 33 90
Net Working Capital (NWC)		 129 182 217 203 101 184 10 56 18 33 90
Net Nonoperating Expense (NNE)		 18 40 20 19 79 120 97 38 20 34 22
Net Nonoperating Obligations (NNO)		 -138 -260 -318 -307 -72 -172 -52 -24 -8.24 -13 -137
Total Depreciation and Amortization (D&A)		 0.65 0.79 1.23 1.19 38 35 38 37 42 42 1.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -5,100.33% -55.48% -50.09% -13.81% -28.64% -19.92% -0.96% -3.67% -11.83% -40.15%
Debt-free Net Working Capital to Revenue		 0.00% 11,860.13% 119.88% 104.74% 30.27% 62.55% 50.86% 29.97% 18.38% 20.55% 38.11%
Net Working Capital to Revenue		 0.00% 11,860.13% 119.88% 97.52% 30.27% 62.55% 4.77% 19.03% 9.39% 20.55% 38.11%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.29) ($3.60) ($1.77) ($2.47) ($2.36) ($2.77) ($1.70) ($0.51) ($0.28) ($0.33) ($0.02)
Adjusted Weighted Average Basic Shares Outstanding		 37.94M 38.83M 48.35M 117.12M 129.86M 153.50M 165.95M 182.78M 187.47M 210.95M 257.16M
Adjusted Diluted Earnings per Share		 ($2.29) ($3.60) ($1.77) ($2.47) ($2.36) ($2.77) ($1.70) ($0.51) ($0.28) ($0.33) ($0.02)
Adjusted Weighted Average Diluted Shares Outstanding		 37.94M 38.83M 48.35M 117.12M 129.86M 153.50M 165.95M 182.78M 187.47M 210.95M 257.16M
Adjusted Basic & Diluted Earnings per Share		 ($2.29) ($3.60) ($1.77) ($2.47) ($2.36) ($2.77) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.47M 37.72M 43.50M 58.04M 118.40M 138.46M 181.23M 184.25M 209.37M 236.23M 267.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -43 -96 -54 -125 -200 -264 -185 -45 -32 -35 16
Normalized NOPAT Margin		 0.00% -6,222.93% -29.62% -60.03% -59.82% -89.76% -87.48% -15.52% -16.57% -22.03% 6.96%
Pre Tax Income Margin		 0.00% -8,843.45% -40.65% -82.76% -85.46% -130.61% -133.25% -32.22% -26.68% -43.33% -1.58%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -85.69 0.00 -98.08 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -62.41 0.00 -68.34 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -85.81 0.00 -98.15 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -62.54 0.00 -68.40 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Akebia Therapeutics

This table displays calculated financial ratios and metrics derived from Akebia Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - 262,635,836.00 265,145,038.00 - 267,879,239.00
DEI Adjusted Shares Outstanding		 - - - - - - - 262,635,836.00 265,145,038.00 - 267,879,239.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - 0.00 0.00 - -0.03
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -13.69% -52.13% -18.49% -22.58% -10.98% -17.26% 75.84% 43.13% 57.01% 23.93% -6.61%
EBITDA Growth		 91.04% 267.90% 64.82% 2,520.33% -9.04% -115.23% 353.73% 148.47% 255.37% 7.52% -127.54%
EBIT Growth		 74.05% 141.72% 40.87% 32.50% -2.29% -884.20% 192.73% 210.07% 144.12% 59.77% -130.52%
NOPAT Growth		 74.14% 140.29% 41.65% 3.01% 4.07% -829.37% 229.26% 330.68% 123.76% 40.21% -124.32%
Net Income Growth		 73.22% 132.08% 33.08% 23.18% -38.30% -3,826.14% 133.98% 102.88% 102.69% 46.31% -248.13%
EPS Growth		 72.41% 133.33% 40.00% 33.33% -25.00% -1,100.00% 133.33% 100.00% 100.00% 50.00% -200.00%
Operating Cash Flow Growth		 -121.20% 95.78% -10.80% -377.38% 6.59% -93.50% 30.08% 321.98% 519.79% 797.02% -56.08%
Free Cash Flow Firm Growth		 -154.08% -43.89% 179.79% -120.30% 80.40% -35.74% -80.01% 554.39% 651.41% 163.54% 144.05%
Invested Capital Growth		 33.29% -102.66% -171.00% 7.05% -6.29% -60.62% -8.21% -73.25% -67.61% -66.74% -104.29%
Revenue Q/Q Growth		 -25.42% 33.65% -41.98% 33.86% -14.25% 24.23% 23.31% 8.96% -5.93% -1.95% -7.08%
EBITDA Q/Q Growth		 -2,885.37% 526.31% -143.82% 153.21% -234.50% 40.46% 695.47% -47.89% -15.90% -197.85% 35.78%
EBIT Q/Q Growth		 -37.24% 115.53% -1,190.31% 57.03% -107.96% -19.05% 187.16% -48.99% -16.64% -208.56% 33.88%
NOPAT Q/Q Growth		 -44.91% 115.05% -861.49% 41.58% -43.32% -14.40% 234.95% 4.25% -85.24% -387.83% 45.10%
Net Income Q/Q Growth		 -29.69% 104.22% -3,038.73% 52.28% -133.50% -13.80% 126.80% -95.96% 118.62% -2,367.41% 26.05%
EPS Q/Q Growth		 -33.33% 112.50% -1,000.00% 55.56% -150.00% 0.00% 130.00% -100.00% 0.00% 0.00% 40.00%
Operating Cash Flow Q/Q Growth		 -297.49% 67.80% -741.94% 48.20% 33.49% 33.29% -204.23% 264.46% 25.78% 10.76% -168.13%
Free Cash Flow Firm Q/Q Growth		 -171.09% 168.43% 297.58% -110.49% 31.36% 324.41% 23.67% 138.54% -16.71% 7.25% 14.52%
Invested Capital Q/Q Growth		 -14.37% 10.41% -0.64% 9.86% -30.79% -35.38% 32.20% -44.32% -26.53% -34.68% 16.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 57.17% 66.78% 64.41% 60.94% 62.16% 56.20% 86.70% 84.12% 84.03% 78.25% 77.05%
EBITDA Margin		 -8.73% 27.86% -17.16% 6.82% -10.70% -5.13% 24.76% 11.84% 10.59% -10.56% -7.30%
Operating Margin		 -31.00% 2.44% -45.81% -19.99% -33.41% -30.77% 23.57% 22.55% 7.57% -14.84% -8.77%
EBIT Margin		 -31.11% 3.61% -45.91% -14.74% -35.74% -34.25% 24.21% 11.33% 10.04% -11.12% -7.91%
Profit (Net Income) Margin		 -34.46% 1.09% -55.16% -19.66% -53.54% -49.04% 10.66% 0.40% 0.92% -21.25% -16.91%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 46.75% 108.98% 101.41%
Interest Burden Percent		 110.78% 30.13% 120.14% 133.41% 149.79% 143.18% 44.03% 3.49% 19.57% 175.33% 210.72%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 53.25% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -752.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -753.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 760.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 425.87% 409.60% 8.39% 133.56% 102.41% 174.03% 3,385.36% 1,610.77% 361.07% 64.49% -78.96%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -23.72% 2.35% -33.95% -10.85% -27.47% -23.73% 16.72% 8.16% 7.91% -8.80% -5.47%
Return on Assets (ROA)		 -26.28% 0.71% -40.78% -14.48% -41.14% -33.98% 7.36% 0.28% 0.72% -16.81% -11.68%
Return on Common Equity (ROCE)		 425.87% 409.60% 8.39% 133.56% 102.41% 174.03% 3,385.36% 1,610.77% 361.07% 64.49% -78.96%
Return on Equity Simple (ROE_SIMPLE)		 138.11% 0.00% 157.88% 119.82% 91.25% 0.00% -184.34% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.13 1.37 -10 -6.11 -8.75 -10 14 14 2.08 -5.99 -3.29
NOPAT Margin		 -21.70% 2.44% -32.06% -13.99% -23.39% -21.54% 23.57% 22.55% 3.54% -10.39% -6.14%
Net Nonoperating Expense Percent (NNEP)		 -12.97% -4.66% 0.93% -39.42% 5,374.05% -119.42% -18.82% -30.19% -2.69% -8.36% -6.39%
Return On Investment Capital (ROIC_SIMPLE)		 - 33.50% - - - 95.45% 19.01% 18.47% 2.33% -7.40% -4.31%
Cost of Revenue to Revenue		 42.83% 33.22% 35.59% 39.06% 37.84% 43.80% 13.30% 15.88% 15.97% 21.75% 22.95%
SG&A Expenses to Revenue		 54.01% 45.26% 78.01% 61.67% 70.85% 59.52% 44.90% 42.51% 49.51% 45.28% 56.84%
R&D to Revenue		 31.70% 17.56% 29.84% 17.52% 22.68% 25.35% 17.01% 17.63% 25.43% 46.25% 27.65%
Operating Expenses to Revenue		 88.17% 64.34% 110.22% 80.93% 95.58% 86.97% 63.13% 61.57% 76.46% 93.09% 85.82%
Earnings before Interest and Taxes (EBIT)		 -13 2.03 -15 -6.43 -13 -16 14 7.08 5.90 -6.41 -4.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.67 16 -5.60 2.98 -4.00 -2.38 14 7.40 6.22 -6.09 -3.91
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 18.45 32.71 17.40 13.10 13.60
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.84 1.20 2.05 1.23 1.63 2.59 2.45 4.69 3.22 1.81 1.60
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.82 1.16 1.98 1.22 1.66 2.51 2.09 4.25 2.69 1.23 1.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 92.01 29.75 41.43 0.00 35.86 56.94 23.79 13.38 71.40
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 55.31 14.21 110.56
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,561.60 48.71 17.67 69.85
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.68 4.27 4.28
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 5.37 0.00 0.00 0.00 0.00 32.85 13.89 5.01 5.41
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.08 -1.13 -1.11 -1.13 -0.76 -0.79 1.89 1.61 1.15 1.48 1.79
Long-Term Debt to Equity		 -0.88 -0.56 -1.11 -1.13 -0.76 -0.79 1.89 1.61 1.15 1.48 1.33
Financial Leverage		 3.24 1.29 -1.01 0.21 0.00 0.27 29.39 20.25 12.99 9.04 -3.48
Leverage Ratio		 -26.24 -23.58 -0.31 -7.83 -4.92 -5.80 -200.10 -124.90 -64.85 -36.03 12.95
Compound Leverage Factor		 -29.07 -7.10 -0.38 -10.44 -7.37 -8.30 -88.10 -4.36 -12.69 -63.17 27.28
Debt to Total Capital		 1,335.41% 846.13% 1,044.16% 889.20% -318.38% -368.79% 65.42% 61.69% 53.39% 59.67% 64.11%
Short-Term Debt to Total Capital		 250.71% 426.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.38%
Long-Term Debt to Total Capital		 1,084.71% 419.20% 1,044.16% 889.20% -318.38% -368.79% 65.42% 61.69% 53.39% 59.67% 47.72%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -1,235.41% -746.13% -944.16% -789.20% 418.38% 468.79% 34.58% 38.31% 46.61% 40.33% 35.89%
Debt to EBITDA		 -2.81 -8.57 7.47 5.33 5.64 -4.30 4.31 3.10 1.87 2.22 13.50
Net Debt to EBITDA		 0.26 2.04 -2.93 -0.21 0.64 1.46 -6.20 -5.94 -4.67 -6.29 -31.41
Long-Term Debt to EBITDA		 -2.28 -4.25 7.47 5.33 5.64 -4.30 4.31 3.10 1.87 2.22 10.05
Debt to NOPAT		 -1.16 -1.07 -1.21 -1.54 -1.57 -1.10 -3.02 84.89 3.84 2.93 13.21
Net Debt to NOPAT		 0.11 0.25 0.47 0.06 -0.18 0.37 4.34 -162.78 -9.56 -8.30 -30.73
Long-Term Debt to NOPAT		 -0.94 -0.53 -1.21 -1.54 -1.57 -1.10 -3.02 84.89 3.84 2.93 9.83
Altman Z-Score		 -8.06 -7.88 -8.33 -9.17 -9.74 -9.06 -5.42 -3.90 -4.00 -4.66 -5.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.38 1.18 1.70 1.04 1.52 1.41 2.23 1.98 1.94 1.55 1.40
Quick Ratio		 0.87 0.82 1.03 0.65 1.01 1.07 1.92 1.77 1.74 1.42 1.30
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -31 21 84 -8.78 -6.03 14 17 40 33 36 41
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -334,750.00% -223,300.00% 0.00% 17,734.13% 36,500.00% 44,470.00% -34,204.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 161.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -37.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -37.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.76 0.65 0.74 0.74 0.77 0.69 0.69 0.72 0.79 0.79 0.69
Accounts Receivable Turnover		 11.20 4.89 8.26 7.07 6.20 4.35 4.19 3.97 4.57 5.80 3.75
Inventory Turnover		 2.09 3.98 2.85 2.92 3.16 3.96 2.62 2.57 2.42 2.48 2.70
Fixed Asset Turnover		 53.05 44.02 0.00 47.72 51.82 54.96 71.55 88.41 112.37 138.05 162.52
Accounts Payable Turnover		 4.25 4.54 0.00 5.97 5.46 4.24 4.82 4.81 4.01 2.17 4.19
Days Sales Outstanding (DSO)		 32.59 74.62 44.21 51.60 58.83 83.92 87.01 91.88 79.78 62.89 97.43
Days Inventory Outstanding (DIO)		 174.78 91.70 127.88 125.09 115.58 92.25 139.55 142.23 151.03 147.31 135.36
Days Payable Outstanding (DPO)		 85.91 80.37 0.00 61.13 66.89 86.13 75.66 75.92 91.00 168.18 87.03
Cash Conversion Cycle (CCC)		 121.46 85.95 172.09 115.56 107.52 90.04 150.90 158.19 139.81 42.03 145.75
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -43 -39 -39 -35 -46 -62 -42 -61 -77 -104 -86
Invested Capital Turnover		 -4.72 -6.71 23.46 -4.77 -3.80 -3.17 -4.55 -4.23 -3.65 -2.84 -3.61
Increase / (Decrease) in Invested Capital		 22 -20 -94 2.67 -2.73 -24 -3.21 -26 -31 -42 -44
Enterprise Value (EV)		 211 225 371 212 282 401 387 866 605 291 259
Market Capitalization		 215 234 383 214 278 415 454 956 724 427 372
Book Value per Share		 ($0.21) ($0.16) ($0.13) ($0.16) ($0.24) ($0.23) $0.10 $0.11 $0.16 $0.12 $0.10
Tangible Book Value per Share		 ($0.76) ($0.67) ($0.54) ($0.53) ($0.56) ($0.50) ($0.15) ($0.11) ($0.07) ($0.10) ($0.12)
Total Capital		 3.19 4.10 2.89 4.28 -12 -10 71 76 89 81 76
Total Debt		 43 35 30 38 38 39 47 47 48 48 49
Total Long-Term Debt		 35 17 30 38 38 39 47 47 48 48 36
Net Debt		 -3.92 -8.24 -12 -1.47 4.34 -13 -67 -90 -119 -137 -114
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 -0.15 0.13 0.08 0.07 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.63 -7.15 4.50 -35 0.39 -19 -0.82 -21 -41 -95 -81
Debt-free Net Working Capital (DFNWC)		 38 36 46 4.80 34 33 113 116 125 90 82
Net Working Capital (NWC)		 30 18 46 4.80 34 33 113 116 125 90 70
Net Nonoperating Expense (NNE)		 5.36 0.76 7.53 2.47 11 13 7.40 14 1.54 6.26 5.77
Net Nonoperating Obligations (NNO)		 -3.92 -8.24 -12 -1.47 4.34 -13 -67 -90 -119 -137 -114
Total Depreciation and Amortization (D&A)		 9.41 14 9.38 9.41 9.37 14 0.31 0.32 0.32 0.32 0.33
Debt-free, Cash-free Net Working Capital to Revenue		 -3.37% -3.67% 2.40% -19.89% 0.23% -11.83% -0.44% -10.49% -18.43% -40.15% -34.66%
Debt-free Net Working Capital to Revenue		 14.81% 18.38% 24.81% 2.75% 20.26% 20.55% 60.87% 56.91% 55.52% 38.11% 35.32%
Net Working Capital to Revenue		 11.69% 9.39% 24.81% 2.75% 20.26% 20.55% 60.87% 56.91% 55.52% 38.11% 29.95%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.08) $0.01 ($0.09) ($0.04) ($0.10) ($0.10) $0.03 $0.00 $0.00 ($0.05) ($0.03)
Adjusted Weighted Average Basic Shares Outstanding		 188.31M 187.47M 204.96M 209.71M 210.35M 210.95M 235.50M 262.57M 264.79M 257.16M 267.05M
Adjusted Diluted Earnings per Share		 ($0.08) $0.01 ($0.09) ($0.04) ($0.10) ($0.10) $0.03 $0.00 $0.00 ($0.05) ($0.03)
Adjusted Weighted Average Diluted Shares Outstanding		 188.31M 187.47M 204.96M 209.71M 210.35M 210.95M 241.60M 271.10M 274.37M 257.16M 267.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 188.39M 209.37M 209.60M 210.29M 218.18M 236.23M 262.64M 265.15M 265.37M 267.88M 268.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.01 0.96 -10 -6.11 -8.75 -10 9.46 9.86 3.11 -5.99 -3.29
Normalized NOPAT Margin		 -21.42% 1.71% -31.94% -13.99% -23.39% -21.54% 16.50% 15.79% 5.30% -10.39% -6.14%
Pre Tax Income Margin		 -34.46% 1.09% -55.16% -19.66% -53.54% -49.04% 10.66% 0.40% 1.97% -19.50% -16.67%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -28.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -20.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -28.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -20.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Akebia Therapeutics (NASDAQ: AKBA) showed a meaningful operational turnaround in Q1 2026, but the company still carries a thin equity cushion and ongoing losses. Revenue declined modestly year over year, yet the company narrowed its net loss sharply and generated stronger operating cash flow than in the prior-year quarter. On the balance sheet, cash remains solid, but liabilities continue to outweigh equity by a wide margin.

  • Revenue remained sizable at $53.5 million in Q1 2026, only slightly below $57.6 million in Q4 2025 and above most quarters from 2024.
  • Gross profit was strong at $41.3 million, with gross margin near 77%, showing the core business can still produce healthy product economics.
  • Operating losses improved sharply to a $4.7 million loss in Q1 2026 from a $12.2 million loss in Q4 2025 and a $14.9 million loss in Q1 2025.
  • Net loss narrowed to $9.1 million, a big improvement from $12.2 million in Q4 2025 and $18.0 million in Q1 2025.
  • Operating cash flow turned negative again, but less severely than earlier periods, with a $21.2 million outflow in Q1 2026 versus a $13.6 million outflow in Q1 2025 and a $4.5 million outflow in Q4 2024.
  • Cash and equivalents were $162.6 million at the end of Q1 2026, up from $137.3 million a year earlier, giving the company a relatively comfortable liquidity position.
  • Shares outstanding continue to rise more slowly than in prior periods, which suggests dilution may be moderating versus the heavier equity issuance seen in 2024 and early 2025.
  • Inventory and receivables remain material, which supports ongoing sales but also ties up working capital.
  • PPE spending was minimal, indicating a light capital intensity profile, but also limited investment in fixed assets.
  • Total liabilities reached $335.1 million, compared with only $27.4 million of common equity, leaving the balance sheet highly leveraged from an accounting standpoint.
  • Retained earnings remain deeply negative at $1.69 billion, reflecting years of accumulated losses.
  • Accrued expenses were very high at $125.1 million, a reminder that a large portion of the liability base is still tied to operating obligations.
  • Interest and other non-operating items still pressured results, limiting how much the improved operating performance translated into bottom-line profitability.

Longer-term trend: Akebia’s quarterly results have improved meaningfully from the much weaker periods in 2022 and early 2023, when the company posted large losses and sometimes negative operating cash flow. Revenue has also become more stable in the $50 million to $60 million range in recent quarters. That said, the company has not yet established consistent profitability, and balance sheet risk remains elevated because equity is still small relative to total liabilities.

Bottom line: AKBA is trending in the right direction operationally, with better margins and smaller losses, but investors should still view it as a turnaround story with financial leverage and dilution risk.

07/26/26 05:00 PM ETAI Generated. May Contain Errors.

Akebia Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Akebia Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Akebia Therapeutics' net income appears to be on a downward trend, with a most recent value of -$5.35 million in 2025, falling from -$60.72 million in 2015. The previous period was -$69.41 million in 2024. See where experts think Akebia Therapeutics is headed by visiting Akebia Therapeutics' forecast page.

Akebia Therapeutics' total operating income in 2025 was $23.50 million, based on the following breakdown:
  • Total Gross Profit: $196.73 million
  • Total Operating Expenses: $173.24 million

Over the last 10 years, Akebia Therapeutics' total revenue changed from $0.00 in 2015 to $236.20 million in 2025, a change of 23,619,600,000.0%.

Akebia Therapeutics' total liabilities were at $343.96 million at the end of 2025, a 27.5% increase from 2024, and a 2,780.2% increase since 2015.

In the past 10 years, Akebia Therapeutics' cash and equivalents has ranged from $42.93 million in 2023 to $228.70 million in 2020, and is currently $184.84 million as of their latest financial filing in 2025.

Over the last 10 years, Akebia Therapeutics' book value per share changed from 4.28 in 2015 to 0.12 in 2025, a change of -97.1%.


Related Companies

Financial statements for NASDAQ:AKBA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
August 6 could be a BIG day for one AI company
One AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...
InvestorPlace | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel